share_log

Biodexa Pharmaceuticals | 424B3: Prospectus

Biodexa Pharmaceuticals | 424B3: Prospectus

Biodexa Pharmaceuticals | 424B3:募資說明書
美股sec公告 ·  05/04 04:13
牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has announced the filing of a prospectus with the SEC for the resale of 115,102,400 Ordinary Shares represented by 287,756 American Depositary Shares (ADSs). The shares are related to series D warrants and placement agent warrants issued in an offering. The selling shareholders, identified in the prospectus, may sell the shares on the market or in private transactions. The ADSs are listed on the NASDAQ Capital Market under the symbol 'BDRX.' The last reported closing price of the ADSs was $1.27 on May 2, 2024. The company will not receive any proceeds from the sale of the ADSs by the selling shareholders but may receive proceeds from the exercise of warrants under certain circumstances. The prospectus also details the company's right to issue and sell shares, the appointment of JPMorgan Chase Bank, N.A. as the depositary, and the legal and financial advisors involved in the process.
Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has announced the filing of a prospectus with the SEC for the resale of 115,102,400 Ordinary Shares represented by 287,756 American Depositary Shares (ADSs). The shares are related to series D warrants and placement agent warrants issued in an offering. The selling shareholders, identified in the prospectus, may sell the shares on the market or in private transactions. The ADSs are listed on the NASDAQ Capital Market under the symbol 'BDRX.' The last reported closing price of the ADSs was $1.27 on May 2, 2024. The company will not receive any proceeds from the sale of the ADSs by the selling shareholders but may receive proceeds from the exercise of warrants under certain circumstances. The prospectus also details the company's right to issue and sell shares, the appointment of JPMorgan Chase Bank, N.A. as the depositary, and the legal and financial advisors involved in the process.
臨床階段的生物製藥公司Biodexa Pharmaceuticals PLC宣佈向美國證券交易委員會提交一份招股說明書,轉售由287,756股美國存托股(ADS)代表的115,102,400股普通股。這些股票與發行中發行的D系列認股權證和配售代理認股權證有關。招股說明書中列出的出售股東可以在市場上或私下交易中出售股票。這些ADS在納斯達克資本市場上市,股票代碼爲 “BDRX”。2024年5月2日,美國證券交易所上一次公佈的收盤價爲1.27美元。該公司不會從出售股票的股東出售ADS中獲得任何收益,但在某些情況下可能會從行使認股權證中獲得收益。招股說明書還詳細說明了公司發行和出售股票的權利、任命摩根大通銀行爲存託人的情況以及參與該過程的法律和財務顧問。
臨床階段的生物製藥公司Biodexa Pharmaceuticals PLC宣佈向美國證券交易委員會提交一份招股說明書,轉售由287,756股美國存托股(ADS)代表的115,102,400股普通股。這些股票與發行中發行的D系列認股權證和配售代理認股權證有關。招股說明書中列出的出售股東可以在市場上或私下交易中出售股票。這些ADS在納斯達克資本市場上市,股票代碼爲 “BDRX”。2024年5月2日,美國證券交易所上一次公佈的收盤價爲1.27美元。該公司不會從出售股票的股東出售ADS中獲得任何收益,但在某些情況下可能會從行使認股權證中獲得收益。招股說明書還詳細說明了公司發行和出售股票的權利、任命摩根大通銀行爲存託人的情況以及參與該過程的法律和財務顧問。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。